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Background: The role of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients is highly
controversial and it is not endorsed by current guidelines. Our meta-analysis aimed to better elucidate its activity, efficacy and
safety.
Material and methods: A systematic search of Medline, Web of Science and conferences proceedings up to 30 October 2017
was carried out to identify randomized controlled trials (RCTs) investigating platinum-based versus platinum-free neoadjuvant
chemotherapy in TNBC patients. Using the fixed and random effects models, pooled odds ratios (ORs) and hazard ratios (HRs)
with 95% confidence intervals (CI) were calculated for pathological complete response (pCR, defined as ypT0/is pN0), event-free
survival (EFS), overall survival (OS) and grade 3 and 4 adverse events (AEs: neutropenia, anemia, thrombocytopenia and
neuropathy).
Results: Nine RCTs (N¼ 2109) were included. Overall, platinum-based neoadjuvant chemotherapy significantly increased pCR
rate from 37.0% to 52.1% (OR 1.96, 95% CI 1.46–2.62, P< 0.001). Platinum-based neoadjuvant chemotherapy remained
significantly associated with increased pCR rate also after restricting the analysis to the three RCTs (N¼ 611) that used the same
standard regimen in both groups of weekly paclitaxel (with or without carboplatin) followed by anthracycline and
cyclophosphamide (OR 2.53, 95% CI 1.37–4.66, P¼ 0.003). Conversely, among the 96 BRCA-mutated patients included in two
RCTs, the addition of carboplatin was not associated with significantly increased pCR rate (OR 1.17, 95% CI 0.51–2.67, P¼ 0.711).
Two RCTs (N¼ 748) reported survival outcomes: no significant difference in EFS (HR 0.72, 95% CI 0.49–1.06, P¼ 0.094) and OS
(HR 0.86, 95% CI 0.46–1.63, P¼ 0.651) was observed.
A significant higher risk of grade 3 and 4 hematological AEs, with no increased risk of grade 3 and 4 neuropathy was observed
with platinum-based neoadjuvant chemotherapy.
Conclusion: In TNBC patients, platinum-based neoadjuvant chemotherapy is associated with significantly increased pCR rates
at the cost of worse hematological toxicities. Platinum-based neoadjuvant chemotherapy may be considered an option in TNBC
patients.
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Introduction
Triple-negative breast cancer (TNBC) accounts for10%–20% of
all breast tumors [1]. Although TNBC is characterized by aggres-
sive behavior, it is particularly sensitive to cytotoxic chemotherapy
(the so-called ‘triple negative paradox’) [2]. In the neoadjuvant set-
ting, TNBC patients have higher response rates to standard
chemotherapy when compared with women affected by hormone
receptor-positive breast cancer. Approximately 30%–40% of
TNBC patients achieve a pathological complete response (pCR)
after standard anthracycline plus cyclophosphamide- and taxane-
based neoadjuvant chemotherapy [3]. The achievement of pCR in
TNBC patients has a strong prognostic value, larger than in other
breast cancer subtypes [4, 5]. Therefore, neoadjuvant chemother-
apy is currently considered the preferred approach for the majority
of TNBC patients with early-stage disease [6].
Platinum agents (i.e. carboplatin and cisplatin) are cytotoxic
DNA damaging compounds leading to DNA strand breaks and
possible consequent cell apoptosis; this peculiar mechanism of
action makes them specially active in cancer cells with DNA re-
pair deficiency such as those harbouring deleterious mutations in
the BRCA genes [7]. Based on the biological rationale for a
heightened susceptibility of TNBC to DNA-damaging com-
pounds [8], several trials have investigated the possible role of
platinum agents as a treatment option in TNBC patients.
Although some of these studies have suggested a possible benefit
for platinum-based neoadjuvant chemotherapy in TNBC
patients, available results are mixed and controversial. Therefore,
according to current breast cancer guidelines, the addition of a
platinum agent to standard neoadjuvant chemotherapy in unse-
lected TNBC patients is not recommended while its use may be
considered in breast cancer patients with deleterious germline
BRCA mutations [9–12].
To provide up to date evidence on this important controversial
topic, we conducted a systematic review and meta-analysis of
randomized controlled trials (RCTs) aiming to better elucidate
the role of platinum-based neoadjuvant chemotherapy in TNBC
patients.
Methods
This was a quantitative synthesis of available RCTs evaluating the
activity, efficacy and safety of platinum-based (experimental
arm) versus platinum-free (control arm) neoadjuvant chemo-
therapy in TNBC patients.
Search strategy and study identification
Eligible studies were identified by a systematic literature search of
the Medline and Web of Science databases, with no language or
date restriction up to 30 October 2017. The search strategy was
carried out using the following keywords: ‘breast cancer’, ‘plat-
inum’, ‘carboplatin’, ‘cisplatin’, ‘neoadjuvant’ and ‘chemother-
apy’. Specific keywords and free text terms were combined with
Boolean operators. A review of conference proceedings from the
European Society for Medical Oncology (ESMO) congress, the
American Society of Clinical Oncology (ASCO) annual meeting,
and the San Antonio Breast Cancer Symposium (SABCS) was
also conducted to identify relevant unpublished studies. Relevant
articles were cross-referenced to confirm that all possible pertin-
ent records were identified.
The systematic literature search was carried out independently
by two authors (FP and ML) and any discrepancies were solved
by discussion with a third author (EdA).
This systematic review and meta-analysis was conducted
according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [13].
This study is registered with the PROSPERO registration num-
ber CRD42018080042; the full protocol is freely available in the
PROPSPERO website.
Selection criteria and data extraction
To be included in the present meta-analysis, eligible studies had
to satisfy all the following inclusion criteria: (i) phase II or III
RCTs; (ii) RCTs including TNBC patients who received
platinum-based neoadjuvant chemotherapy in the experimental
arm and platinum-free neoadjuvant chemotherapy in the control
arm (for RCTs including patients with breast cancer subtypes
other than TNBC, only those with available results in the TNBC
cohort were included); (iii) studies with available information on
pCR rates in the experimental and control arms to estimate the
odds ratio (OR) and 95% confidence intervals (CI).
Exclusion criteria were: (i) non-RCTs conducted to evaluate
the role of platinum-based neoadjuvant chemotherapy in TNBC
patients; (ii) RCTs investigating platinum-based neoadjuvant
chemotherapy in patients with breast cancer subtypes other than
TNBC; (iii) ongoing studies with results not presented or pub-
lished at the time of the literature search.
The following variables were extracted from all the included RCTs,
if available: name of the trial, year of publication, study design, num-
ber of randomized patients, germline BRCA mutational status, type
and dose of chemotherapy administered, number of patients with
pCR, objective response rate (ORR), event-free survival (EFS) and
overall survival (OS) and grade 3 and 4 adverse events (AEs: neutro-
penia, anemia, thrombocytopenia and neuropathy) in the platinum-
based and platinum-free neoadjuvant chemotherapy arms.
Study objectives
The primary objective of this meta-analysis was to compare the
activity of platinum-based versus platinum-free neoadjuvant
chemotherapy in TNBC patients, in terms of pCR (defined as no
residual invasive tumor in both the breast and the axilla, i.e.
ypT0/is pN0). Four main analyses were conducted including: (i)
all RCTs irrespective of the chemotherapy backbone; (ii) only
RCTs in which anthracycline- and taxane-based neoadjuvant
chemotherapy was used in both treatment arms; (iii) only RCTs
in which the same neoadjuvant chemotherapy backbone (with or
without a platinum agent) was administered in both treatment
arms; (iv) only RCTs that used the same standard neoadjuvant
chemotherapy regimen of weekly paclitaxel (with or without a
platinum agent) followed by anthracycline plus cyclophospha-
mide in both treatment arms. In addition, a further analysis was
conducted to assess the benefit of platinum-based neoadjuvant
chemotherapy according to germline BRCA mutational status.
Secondary objectives were to evaluate the activity, efficacy and
safety of platinum-based versus platinum-free neoadjuvant
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chemotherapy in TNBC patients in terms of: (i) ORR; (ii) EFS
and OS; (iii) grade 3 and 4 AEs (neutropenia, anemia, thrombo-
cytopenia and neuropathy).
Statistical analysis
ORs and 95% CI were calculated for the effect of platinum-based
versus platinum-free neoadjuvant chemotherapy for pCR, ORR,
grade 3 and 4 AEs. An OR> 1 indicates higher pCR, ORR and
grade 3 and 4 AEs rates in the platinum-based neoadjuvant
chemotherapy group. An OR< 1 indicates lower pCR, ORR and
grade 3 and 4 AEs rates in the platinum-based neoadjuvant
chemotherapy group. Hazard ratios (HRs) and 95% CI were cal-
culated for the effect of platinum-based versus platinum-free
neoadjuvant chemotherapy in terms of EFS and OS. HR< 1 indi-
cates improved EFS and OS with platinum-based neoadjuvant
chemotherapy. HR> 1 indicates reduced EFS and OS with
platinum-based neoadjuvant chemotherapy.
The Mantel–Haenzel method was used to obtain fixed effects
model of the pooled ORs [14], and standard checks of the homo-
geneity assumption was performed [15]. In the presence of sig-
nificant heterogeneity among the trials, the more appropriate
method of DerSimonian and Laird was computed for the pooled
estimate of the ORs using the random effects model [16]. To ob-
tain a quantitative measure of the degree of inconsistency in the
results of the studies, the Higgins I2 index was computed [17].
The likelihood of publication bias was assessed by visual inspec-
tion of funnel plot for study size against treatment effect [18] and
with Harbords’ asymmetry test [19].
The pooled ORs and HRs were considered statistically significant if
the 95% CI did not include 1.0, with a P value of<0.05 (two-sided).
Sensitivity analyses (aiming to define whether the pooled OR
and HR estimates were stable or they mainly depended on one
single or a few of the included RCTs) were conducted by recalcu-
lating the pooled OR and HR estimates after exclusion of each in-
dividual study.
The STATA software version 13.1 (StataCorp LP, College
Station, TX) was used for all statistical analyses and for the gener-
ation of the forest plots.
Results
The systematic literature search returned 1328 records (Figure 1).
After the exclusion of 1316 non-relevant records, 12 potentially
eligible RCTs were considered [20–31]. Among them, two were
updates of prior published studies [27, 29] and one was a second-
ary analysis of an already included RCT [28]. Hence, nine differ-
ent RCTs were included in the current meta-analysis (Figure 1).
Two RCTs were published only in abstract form [24, 26]. The
two RCTs conducted by the German Breast Group included both
TNBC and HER2-positive breast cancer patients [21, 26], and the
UMIN000003355 RCT included also hormone receptor-positive/
HER2-negative breast cancer patients [23]: for the purpose of the
present meta-analysis, only data pertaining to TNBC patients
participating in these RCTs were considered.
A total of 2109 TNBC patients were included in the present
meta-analysis, of whom 1046 (49.6%) received platinum-based
and 1063 (50.4%) platinum-free chemotherapy.
Figure 1. The PRISMA ﬂow chart summarizing the process for the identiﬁcation of eligible randomized controlled trials. ESMO, European
Society for Medical Oncology; ASCO, American Society of Clinical Oncology; SABCS, San Antonio Breast Cancer Symposium; TNBC, triple-
negative breast cancer; RCTs, randomized controlled trials.
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Main characteristics of the included RCTs are reported in
Table 1. All but one [24] RCTs used carboplatin as platinum agent.
In seven RCTs (N¼ 1698 patients), anthracycline- and taxane-
based neoadjuvant chemotherapy was used in both groups [20–24,
26, 31]. The same chemotherapy backbone (with or without car-
boplatin) was used in five of the included RCTs (N¼ 1234
patients) [20–23, 31]. The same standard chemotherapy regimen
of weekly paclitaxel (with or without carboplatin) followed by
anthracycline plus cyclophosphamide in both groups was used in
three of the included RCTs (N¼ 611patients) [22, 23, 31].
All TNBC patients included in the GeparSixto GBG66 study
[21] and half of those enrolled in the CALGB study [22] received
also bevacizumab in both the platinum-based and platinum-free
chemotherapy arms. Two out of the three arms of the BrighTNess
trial were considered for the purpose of the present meta-analysis:
arm B [weekly paclitaxel plus carboplatin plus veliparib placebo
(i.e. platinum-based neoadjuvant chemotherapy arm)] and arm C
[weekly paclitaxel plus carboplatin placebo plus veliparib placebo
(i.e. platinum-free neoadjuvant chemotherapy arm)] [31].
Germline BRCA mutational status was available for 609
patients in two RCTs [28, 31]. A total of 96 BRCA-mutated
patients were included, 50 of the 291 patients (17.2%) included
in the GeparSixto GBG66 study and 46 of the 318 patients
(14.5%) randomized in the BrighTNess trial.
Table 1. Main characteristics of the randomized controlled trials included in the present meta-analysis
Study Study
design
Primary
end point
Secondary end points Treatment arms TNBC
patients, n
GEICAM/2006-03 [20] Phase II ypT0/is ypT0/is pN0, clinical response rate, safety, EC—DCb 47
EC—D 46
GeparSixto GBG66 [21] Phase II ypT0 pN0 ypT0/is pN0, clinical response rate, safety, efﬁcacy PþDoxþBevþCb 158
PþDoxþBev 157
CALGB 40603 Alliance [22] Phase II ypT0/is ypT0/is pN0, safety, RFS and OS PþCb6Bev! ddAC 221
P6Bev! ddAC 212
UMIN000003355 [23] Phase II ypT0/is pN0 Clinical response rate, safety, DFS PCb! CEF 37
P! CEF 38
Aguilar Martinez et al. [24] Phase II ypT0/is pN0 Clinical response rate, safety CisþP! CisþDox 30
P! FAC 31
NCT01276769 [25] Phase II ypT0/is pN0 ORR, safety, RFS, OS PCb 44
EP 43
GeparOcto GBG84 [26] Phase III ypT0/is pN0 Toxicity, DFS, OS PDoxCb 203
DdEPC 200
WSG-ADAPT [30] Phase II ypT0/is pN0 Toxicity, EFS, OS Nab-PþCb 146
Nab-PþGem 178
BrighTNess [31] Phase III ypT0/is pN0 Clinical response rate, toxicity, EFS, OS PþCb! AC 160
P! AC 158
EC-DCb: epirubicin 90mg/m2 plus cyclophosphamide 600mg/m2 for four cycles followed by docetaxel 75mg/m2 plus carboplatin area under curve (AUC)
6 for four cycles; EC-D: epirubicin 90mg/m2 plus cyclophosphamide 600mg/m2 for four cycles followed by docetaxel 100mg/m2; PþDoxþ BevþCb:
paclitaxel 80mg/m2 plus nonpegylated liposomal doxorubicin 20mg/m2, both once a week for 18weeks plus bevacizumab 15mg/kg intravenously every
3weeks simultaneously plus carboplatin at a dose of 2.0 AUC, once every week for 18weeks; PþDoxþ Bev: paclitaxel 80mg/m2 plus nonpegylated liposo-
mal doxorubicin 20mg/m2, both once a week for 18weeks plus bevacizumab 15mg/kg intravenously every 3weeks simultaneously with all cycles;
PþCb6 Bev ! ddAC: paclitaxel 80mg/m2 once per week for 12weeks concurrent carboplatin AUC 6 once every 3weeks for four cycles, followed by
doxorubicin 60mg/m2 plus cyclophosphamide 600mg/m2 once every 2weeks for four cycles, and/or bevacizumab 10mg/kg once every 2weeks for nine
cycles; P6 Bev ! ddAC: paclitaxel 80mg/m2 once per week for 12weeks followed by doxorubicin 60mg/m2 plus cyclophosphamide 600mg/m2
once every 2weeks for four cycles, and/or bevacizumab 10mg/kg once every 2weeks for nine cycles; PCb ! CEF: four cycles of carboplatin AUC 5
every 3weeks concurrent weekly paclitaxel (days 1, 8, 15) followed by four cycles of cyclophosphamide 500mg/m2/plus epirubicin 100 mg/m2 plus 50-
ﬂuorouracile 500mg/m2 every 3weeks; P! CEF: weekly paclitaxel (days 1, 8, 15) followed by four cycles of cyclophosphamide 500mg/m2/plus epirubicin
100 mg/m2 plus 50-ﬂuorouracile 500mg/m2 every 3weeks; Cisþ P ! CisþDox: cisplatin 30mg/m2 plus weekly paclitaxel 80mg/m2 for 12weeks, fol-
lowed to cisplatin 75mg/m2 plus doxorubicin 50mg/m2 every 3weeks for four cycles; P! FAC: weekly paclitaxel 80mg/m2 for 12weeks followed by 50-
ﬂuorouracile 500mg/m2 plus doxorubicin 50mg/m2 plus cyclophosphamide 500mg/m2 every 3weeks for four cycles; PCb: paclitaxel 175mg/m2 on day 1
plus carboplatin AUC 5 on day 2, every 3weeks for four to six cycles; EP: epirubicin 75mg/m2 on day 1 and paclitaxel 175mg/m2 on day 2 every 3weeks
for four to six cycles; PDoxCb: paclitaxel 80mg/m2 weekly simultaneously with nonpegylated liposomal doxorubicin 20mg/m2 simultaneously with carbo-
platin AUC 1.5 weekly for 18weeks; ddEPC: epirubicin 150mg/m2 every 2weeks for three cycles followed by paclitaxel 225mg/m2 every 2weeks for three
cycles followed by cyclophosphamide 2000mg/m2 every 2weeks for three cycles; Nab-PþCb: nab-paclitaxel 125mg/m2 plus carboplatin AUC 2 day 1, 8
every 3weeks for 12weeks; Nab-PþGem: nab-paclitaxel 125mg/m2 plus gemcitabine 1000mg/m2 day 1, 8 every 3weeks for 12weeks; PþCb!AC: pacli-
taxel 80mg/m2 weeklyþCb AUC 6 every 3weeks for 12weeks followed by doxorubicin 60mg/m2 plus cyclophosphamide 600mg/m2 every 2 or 3weeks;
P!AC: paclitaxel 80mg/m2 weekly followed by doxorubicin 60mg/m2 plus cyclophosphamide 600mg/m2 every 2 or 3weeks; TNBC, triple-negative breast
cancer; RFS, relapse-free survival; DFS, disease-free survival; EFS, event-free survival; OS, overall survival; ORR, objective response rate.
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The National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI CTCAE) version 3.0 or 4.0 was used to
classify the observed AEs in the included RCTs; two RCTs did not
report the specific rates of grade 3 and 4 AEs in the two treatment
arms [24, 26].
Pathological complete response rates
Overall, including all the nine RCTs, 938 of 2109 (44.5%) patients
achieved a pCR after neoadjuvant treatment, 545 of 1046 (52.1%)
in the platinum-based chemotherapy group and 393 of 1063
(37.0%) in the platinum-free chemotherapy group (OR 1.96,
95% CI 1.46–2.62, P< 0.001; I2¼ 56.3%, P¼ 0.019) (Figure 2A).
The sensitivity analysis showed a stability of the pooled OR esti-
mates with only marginal fluctuations by excluding each study at
a time (supplementary Table S1, available at Annals of Oncology
online). The funnel plot (Figure 2B) and the Harbords asym-
metry test (P¼ 0.282) showed no evidence of publication bias.
In the seven RCTs that used anthracycline- and taxane-based
chemotherapy in both arms [20–24, 26, 31], 797 of 1698 (46.9%)
Figure 2. (A) Odds ratio for pathological complete response of platinum-based (Platinum) versus platinum-free (Controls) neoadjuvant
chemotherapy in all included randomized controlled trials (the size of the squares is proportional to the weight of each study). (B) Funnel
plot with pseudo 95% conﬁdence limits for the effect of platinum-based neoadjuvant chemotherapy estimated from individual studies (hori-
zontal axis) against the study size (vertical axis): publication bias is unlikely as suggested by the symmetric inverted funnel shape. OR, odds
ratio; CI, conﬁdence intervals.
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patients achieved a pCR after neoadjuvant treatment, 461 of 856
(53.9%) in the platinum-based chemotherapy group and 336 of
842 (39.9%) in the platinum-free chemotherapy group (OR 1.85,
95% CI 1.31–2.61, P< 0.001; I2¼ 62.1%, P¼ 0.015) (Figure 3A).
Supplementary Table S2, available at Annals of Oncology online
displays the sensitivity analysis.
In the five RCTs with the same chemotherapy backbone (with
or without carboplatin) in both groups [20–23, 31], 565 of 1234
(45.8%) patients achieved a pCR after neoadjuvant treatment,
338 of 623 (54.2%) in the platinum-based chemotherapy group,
and 227 of 611 (37.1%) in the platinum-free chemotherapy
group (OR 2.04, 95% CI 1.39–3.00, P< 0.001; I2¼ 57.7%,
P¼ 0.051) (Figure 3B). Supplementary Table S3, available at
Annals of Oncology online displays the sensitivity analysis.
Three RCTs investigated the addition of platinum agents to the
same standard neoadjuvant chemotherapy regimen of weekly
paclitaxel (with or without carboplatin) followed by anthracy-
cline plus cyclophosphamide [22, 23, 31]. For the purpose of this
analysis, only patients included in the two arms without bevaci-
zumab of the CALGB study were included. In these three RCTs,
Figure 3. Odds ratios for pathological complete response of platinum-based (Platinum) versus platinum-free (Controls) neoadjuvant chemo-
therapy in the randomized controlled trials using: (A) anthracycline- and taxane-based chemotherapy in both treatment arms; (B) the same
chemotherapy backbone in both treatment arms; (C) the same standard neoadjuvant chemotherapy regimen in both treatment arms. The
size of the squares is proportional to the weight of each study. OR, odds ratio; CI, conﬁdence intervals.
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270 of 611 (44.2%) patients achieved a pCR after neoadjuvant ther-
apy, of whom 169 of 308 (54.9%) in the platinum-based chemo-
therapy group and 101 of 303 (33.3%) in the platinum-free
chemotherapy group (OR 2.53, 95% CI 1.37–4.66, P¼ 0.003;
I2¼ 65.8%, P¼ 0.054) (Figure 3C). Supplementary Table S4, avail-
able at Annals of Oncology online displays the sensitivity analysis.
Two RCTs reported pCR rates according to germline BRCA mu-
tational status [28, 31]: a total of 96 BRCA-mutated patients and 513
patients withoutBRCAmutations were included in these analyses.
Among BRCA-mutated patients, 54 of 96 (56.2%) achieved a
pCR, 29 of 50 (58.0%) in the platinum-based chemotherapy
group and 25 of 46 (54.3%) in the platinum-free chemotherapy
group (OR 1.17, 95% CI 0.51–2.67, P¼ 0.711; I2¼ 0.0%,
P¼ 0.615) (Figure 4A).
Among patients without BRCA mutations, 230 of 513 (44.8%)
achieved a pCR, of whom 146 of 256 (57.0%) in the platinum-
based chemotherapy group and 84 of 257 (32.7%) in the
platinum-free chemotherapy group (OR 2.72, 95% CI 1.71–4.32,
P< 0.001; I2¼ 39.3%, P¼ 0.199) (Figure 4B).
Objective response rate
Five RCTs reported the ORR at the end of neoadjuvant chemo-
therapy [20, 21, 23, 25, 31]; the methods of assessment used in
these RCTs are reported in the supplementary Table S5, available
at Annals of Oncology online.
Overall, the ORR after neoadjuvant therapy was 81.2% (1031
of 1269 patients), 86.3% (550 of 637) in the platinum-based
chemotherapy group and 76.1% (481 of 632) in the platinum-
free chemotherapy group (OR 1.97, 95% CI 1.11–3.49, P< 0.001;
I2¼ 68.8%, P¼ 0.012) (supplementary Figure S1, available at
Annals of Oncology online). Supplementary Table S6, available at
Annals of Oncology online displays the sensitivity analysis.
EFS and OS
Two RCTs reported the survival outcomes [27, 29]. Median
follow-up was 39 months in the CALGB study [27] and
47.3 months in the GeparSixto GBG66 study [29].
No significant differences in EFS (HR 0.72, 95% CI 0.49–1.06,
P¼ 0.094; I2¼ 33.0%, P¼ 0.222) (Figure 5A) nor in OS (HR 0.86,
95% CI 0.46–1.63, P¼ 0.651; I2¼ 63.9%, P¼ 0.096) (Figure 5B)
were observed.
Grade 3 and 4 adverse events
The Geparsixto GBG66 and UMIN000003355 RCTs did not re-
port the specific rates of AEs in the subgroup of TNBC patients
[21, 23]. However, the results of these two RCTs were included in
the present safety analysis, under the assumption that the risk of
presenting AEs should not have been influenced by hormone re-
ceptor status. Figure 6 displays the safety profile overview for
grade 3 and 4 AEs in the platinum-based versus platinum-free
chemotherapy group.
Neutropenia. Seven RCTs reported the rates of grade 3 and 4
neutropenia [20–23, 25, 30, 31]. Overall, 772 of 2030 (37.8%)
patients developed grade 3 and 4 neutropenia after neoadjuvant
treatment, 535 of 1007 (53.1%) in the platinum-based chemo-
therapy group and 237 of 1023 (23.2%) in the platinum-free
chemotherapy group (OR 3.19, 95% CI 1.55–6.54, P¼ 0.002;
I2¼ 90.0%, P¼ 0.000) (supplementary Figure S2 and Table S7,
available at Annals of Oncology online).
Anemia. Six RCTs reported the rates of grade 3 and 4 anemia
[20–23, 30, 31]. Overall, 108 of 1939 (5.6%) patients developed
grade 3 and 4 anemia after neoadjuvant treatment, 104 of 960
(10.8%) in the platinum-based chemotherapy group and 4 of 979
(0.4%) in the platinum-free chemotherapy group (OR 15.01,
95% CI 4.86–46.30, P< 0.001; I2¼29.6%, P¼ 0.213) (supple-
mentary Figure S3 and Table S8, available at Annals of Oncology
online).
Thrombocytopenia. Seven RCTs reported the rates of grade 3
and 4 thrombocytopenia [20–23, 25, 30, 31]. Overall, 121 of 2030
(6.0%) patients developed grade 3 and 4 thrombocytopenia after
neoadjuvant treatment, 111 of 1007 (11.0%) in the platinum-
based chemotherapy group and 10 of 1023 (1.0%) in the
platinum-free chemotherapy group (OR 8.32, 95% CI 2.88–
23.98, P <0.001; I2 ¼ 35.5%, P¼ 0.158) (supplementary Figure
S4 and Table S9, available at Annals of Oncology online).
Figure 3. Continued.
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Neuropathy. Six RCTs reported the rates of grade 3 and 4 neur-
opathy [21–23, 25, 30, 31]. Overall, 70 of 1937 (3.6%) patients
developed grade 3 and 4 neuropathy after neoadjuvant treatment,
35 of 960 (3.6%) in the platinum-based chemotherapy group and
35 of 977 (3.6%) in the platinum-free chemotherapy group (OR
1.05, 95% CI 0.64–1.71, P¼ 0.854; I2¼0.0%, P¼ 0.565) (supple-
mentary Figure S5 and Table S10, available at Annals of Oncology
online).
Discussion
This is the largest and most up to date meta-analysis assessing the
activity, efficacy and safety of platinum-based chemotherapy as
neoadjuvant treatment in TNBC patients. We observed that
platinum-based neoadjuvant chemotherapy is associated with
significant higher pCR rates at the cost of greater risk of hemato-
logical toxicities. In the two RCTs reporting survival outcomes,
no significant difference was observed in EFS and OS. Notably,
BRCA-mutated patients experienced overall high pCR rates
without significant further effect observed with the addition of
carboplatin.
In a prior meta-analysis including five RCTs (N¼ 745) using
different chemotherapy regimens, platinum-based neoadjuvant
chemotherapy was associated with higher pCR rates in TNBC
patients [risk ratio (RR) 1.45, 95% CI 1.25–1.68, P< 0.0001].
However, no clear indication on the added role of platinum
agents in patients receiving standard anthracycline- and taxane-
based neoadjuvant chemotherapy could be obtained from this
meta-analysis and no data on survival outcomes or germline
BRCA mutational status were reported. Moreover, following this
meta-analysis, additional RCTs investigated the role of platinum-
based neoadjuvant chemotherapy in TNBC patients.
Nevertheless, available results from single studies have been con-
sidered insufficient to recommend the use of a platinum agent as
standard component of the neoadjuvant chemotherapy backbone
in unselected TNBC patients [9–12].
The present meta-analysis including nine RCTs (N¼ 2109)
provides updated evidence on the debated role of platinum-
based neoadjuvant chemotherapy in TNBC patients. A significant
Figure 4. Odds ratios for pathological complete response of platinum-based (Platinum) versus platinum-free (Controls) neoadjuvant chemo-
therapy in: (A) BRCA-mutated breast cancer patients; (B) breast cancer patients without BRCA mutations. The size of the square is proportional
to the weight of each study. OR, odds ratio; CI, conﬁdence intervals.
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Figure 5. Hazard ratios for event-free survival (A) and overall survival (B) of platinum-based (Platinum) versus platinum-free (Controls) neoad-
juvant chemotherapy. The size of the squares is proportional to the weight of each study. HR, hazard ratio; CI, conﬁdence intervals.
Figure 6. Safety proﬁle overview. Odds ratios for grade 3 and 4 neutropenia, grade 3 and 4 anemia, grade 3 and 4 thrombocytopenia and
grade 3 and 4 neuropathy in the platinum-based (Platinum) versus platinum-free (Controls) neoadjuvant chemotherapy. OR, odds ratio; CI,
conﬁdence intervals.
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absolute 15.1% increased pCR rate was observed with the use of
platinum-based neoadjuvant chemotherapy (OR 1.96, 95% CI
1.46–2.62, P< 0.001). Even when considering only the five RCTs
in which the same anthracycline-and taxane-based chemotherapy
backbone was used in both groups, the addition of carboplatin
continued to provide a significant added benefit (absolute 17.1%
increased pCR rate; OR 2.04, 95% CI 1.39–3.00, P< 0.001).
Importantly, the beneficial effect of adding carboplatin did not
change and was even more important when the analysis was
restricted to the three RCTs in which patients received the current
standard neoadjuvant chemotherapy with weekly paclitaxel fol-
lowed by anthracycline and cyclophosphamide (absolute 21.6%
increased pCR rate; OR 2.53, 95% CI 1.37–4.66, P¼ 0.003).
A rather high heterogeneity was observed in the pCR analyses.
However, a positive effect for platinum-based neoadjuvant
chemotherapy was shown in most of the included trials with the
exception particularly of the GEICAM/2006-03 study [20]. Of note,
in this study, only basal-like TNBC (defined as hormonal receptor-
negative/HER2-negative and cytokeratin 5/6 or EGFR-positive)
patients were included, and a lower dose of taxane (docetaxel,
75 mg/m2) was administered in the platinum-based chemotherapy
arm when compared with the platinum-free chemotherapy arm
(docetaxel, 100 mg/m2). Moreover, unlike all the other trials
included in the present meta-analysis, patients enrolled in the
GEICAM/2006-03 study received the alkylating agent cyclophos-
phamide before platinum-based chemotherapy. Hence, it is not
possible to exclude that a prior treatment with DNA damaging
agents may reduce the likelihood of benefitting from the addition
of a platinum agent to standard neoadjuvant chemotherapy.
Although the achievement of pCR after neoadjuvant chemother-
apy has a strong positive prognostic value in TNBC [4, 5], it is still
unclear whether an increase in pCR rates translates into improved
survival outcomes. Obtaining data on these crucial clinical end
points remains critical. Only two RCTs (N¼ 748 patients) reported
survival outcomes [27, 29]; although both studies were underpow-
ered to detect a potential survival benefit, significantly improved
survival outcomes were observed with the addition of carboplatin
in patients without germline BRCA mutations in the GeparSixto
GBG66 study [28]. Nevertheless, the pooled results showed no sig-
nificant difference in both EFS (HR 0.72, 95% CI 0.49–1.06,
P¼ 0.094) and OS (HR 0.86, 95% CI 0.46–1.63, P¼ 0.651).
Survival outcomes from the other RCTs and particularly from the
BrighTNess trial (one of the largest RCT in this setting that reported
a nearly doubling in pCR rates with the addition of carboplatin to
standard neoadjuvant chemotherapy and with available informa-
tion onBRCA mutational status) are awaited to better assess the po-
tential long-term benefit of this treatment strategy [31].
Our meta-analysis showed a significant higher incidence of
grade 3 and 4 hematological AEs using platinum-based neoadju-
vant chemotherapy. Hence, breast cancer patients treated with
platinum-based therapy may experience a possible greater inci-
dence of treatment discontinuations and dose reductions [21,
22]. For these reasons, optimal patient’s selection, a proper coun-
selling on the pros and contras of adding a platinum agent to
standard neoadjuvant chemotherapy as well as close clinical
follow-up during treatment are crucial on this regard. The WSG-
ADAPT trial has recently reported evidence on the occurrence of
few dose reductions and manageable toxicity using an alternative
weekly schedule [30]. Specifically, in this trial, carboplatin was
administered with an area under the curve (AUC) of 2 together
with nanoparticle albumin-bound paclitaxel with the schedule 2
weeks on 1 week off. Based also on data coming from the treat-
ment of other cancers types [32], a weekly regimen may be the
best compromise to escalate treatment activity while maintaining
a more tolerable hematological toxicity profile.
Up to 15% of TNBC patients are found to carry a deleterious
germline BRCA mutation [33]. Therefore, germline BRCA testing
is recommended in all TNBC patients diagnosed up to 60 years of
age [34]. As the BRCA genes are critical regulators of the DNA re-
pair machinery for the maintenance of genomic stability, the loss
of BRCA function may render these tumors particularly sensitive
to DNA damaging agents, including platinum agents [35]. Based
on this strong biologic rationale, several studies have investigated
the possible role of platinum agents in the treatment of BRCA-
mutated breast cancer patients in both the metastatic and neoadju-
vant settings. The Triple Negative Trial (TNT) showed that carbo-
platin has similar performance than docetaxel as first-line therapy
in unselected metastatic TNBC patients but led to a doubling in
both ORR (68% versus 33.3%, P¼ 0.03) and progression-free sur-
vival (6.8 versus 4.4 months, P¼ 0.002) in BRCA-mutated patients
[36]. Taking into account these results, current guidelines endorse
the use of platinum-based chemotherapy as the preferred option
in patients with BRCA-associated metastatic TNBC previously
exposed to anthracyclines and taxanes [37]. In the neoadjuvant
setting, several non-RCTs showed that single-agent platinum-
based therapy is an active regimen in a high proportion of
BRCA-mutated breast cancer patients, especially in those with
TNBC [38, 39]. However, available data on the benefit of adding a
platinum agent in BRCA-mutated patients receiving standard neo-
adjuvant chemotherapy are more limited and controversial. So far,
only two RCTs reported pCR results according to germline BRCA
mutational status [28, 31]. Pooled results from these RCTs showed
that the addition of carboplatin to paclitaxel followed by anthracy-
cline plus cyclophosphamide was not associated with a significant
increased pCR rate in BRCA-mutated breast cancer patients (OR
1.17, 95% CI 0.51–2.67, P¼ 0.711) while the benefit was present in
patients without BRCA mutations (OR 2.72, 95% CI 1.71–4.32,
P< 0.001). However, no solid conclusions can be drawn on this re-
gard considering the limited number of BRCA-mutated patients
(N¼ 96) included in the analysis. Notably, an overall higher pCR
rate was observed for the platinum-free regimen in this patient
population (54.3%) when compared with the pCR rate in patients
without BRCA mutations (32.7%). These findings may suggest an
increased vulnerability of these tumors (characterized by limited
DNA repair capacities) to anthracycline-induced single-stranded
and double-stranded DNA breaks [28]. Further research efforts are
warranted to define the best chemotherapy regimen for BRCA-
mutated breast cancer patients in the early setting.
Taken together, the findings of our meta-analysis question the
current recommendation to possibly consider the use of
platinum-based neoadjuvant chemotherapy only in BRCA-
mutated patients. On this regard, prospective validation of bio-
markers predicting sensitivity to platinum agents is required to
better identify the group of TNBC patients with an increased like-
lihood of deriving benefit from the use of platinum-based neoad-
juvant chemotherapy [40–42].
Some limitations of the present analysis should be considered
in the interpretation of our findings. This is a meta-analysis based
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on abstracted data: thus, without individual patient data, the as-
sociation between treatment benefit and toxicity with other im-
portant factors (including patient’s age, dose and length of
chemotherapy) was not possible to be evaluated. Moreover,
results of two included RCTs are currently available only in ab-
stract form. Finally, data on survival outcomes as well as treat-
ment effect according to germline BRCA mutational status have
been reported so far by only two RCTs. Nevertheless, these limita-
tions should not influence the overall interpretation of our results
that provide valuable information on the debated role of the add-
ition of platinum agents to standard neoadjuvant chemotherapy
in TNBC patients. Specifically, these findings give updated point
estimates on the benefits and risks of including a platinum agent
as part of neoadjuvant systemic therapy that may help physicians
and patients during treatment decision-making.
In conclusion, our meta-analysis showed that platinum-based
neoadjuvant chemotherapy was associated with significant
increased pCR rates in TNBC patients at the cost of worse hema-
tological toxicities. These findings suggest that the addition of a
platinum agent to standard neoadjuvant anthracycline- and
taxane-based chemotherapy may be considered an option in
TNBC patients. Long-term follow-up analysis from all the RCTs
and additional subgroup analyses according to germline BRCA
mutational status are awaited to further clarify the role of
platinum-based chemotherapy as neoadjuvant treatment of
TNBC patients.
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